https://www.selleckchem.com/pr....oducts/way-316606.ht
e adherence and monitoring, and mitigate treatment delays. There was a wide range of adherence to biologic infusions in this IBD cohort with poorer adherence associated with patient related factors. Conversely, objectively measured remission was strongly associated with adherence. This emphasises the need for targeted interventions to improve adherence and monitoring, and mitigate treatment delays. Familial hypercholesterolemia (FH) is a genetic disease that affects millions of people worldwide. The study protocol FHBGEP was design t
Curtir
Comentario
Compartilhar
